PROFNAIT: Collaborating To Combat Rare Disease
This article was originally published in Start Up
Executive Summary
Prophylix Pharma is set to be the first company to begin clinical trials for a prophylactic for fetal and neonatal alloimmune thrombocytopenia, a rare but serious disorder that can cause serious bleeding in babies' brains. Its candidate, NAITgam, is being developed under the auspices of the PROFNAIT consortium, an innovative collaborative project involving 11 Northern European universities, hospitals, research organizations, companies, and blood banks.